Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome.

× No keyword cloud information.

15 in total

1. A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults.

Authors: Miriam Giraldez; Katarzyna Puto
Journal: Eur J Haematol Date: 2010-04-12 Impact factor: 2.997

Review 2. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.

Authors: Mitchell S Cairo; Bertrand Coiffier; Alfred Reiter; Anas Younes
Journal: Br J Haematol Date: 2010-03-16 Impact factor: 6.998

3. Managing tumor lysis syndrome in 2010.

Authors: Morie A Gertz
Journal: Leuk Lymphoma Date: 2010-02

4. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.

Authors: Michael Eaddy; Brian Seal; Muralikrishna Tangirala; Elizabeth Hackney Davies; Ken O'Day
Journal: Am J Health Syst Pharm Date: 2010-12-15 Impact factor: 2.637

Review 5. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.

Authors: Daniel Kl Cheuk; Alan Ks Chiang; Godfrey Cf Chan; Shau Yin Ha
Journal: Cochrane Database Syst Rev Date: 2010-06-16

6. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.

Authors: Margit Hummel; Dieter Buchheidt; Sebastian Reiter; Jörg Bergmann; Katja Adam; Rüdiger Hehlmann
Journal: Eur J Haematol Date: 2005-12 Impact factor: 2.997

7. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial.

Authors: C H Pui; S Jeha; D Irwin; B Camitta
Journal: Leukemia Date: 2001-10 Impact factor: 11.528

Review 8. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.

Authors: Bertrand Coiffier; Arnold Altman; Ching-Hon Pui; Anas Younes; Mitchell S Cairo
Journal: J Clin Oncol Date: 2008-06-01 Impact factor: 44.544

9. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.

Authors: Margit Hummel; Sebastian Reiter; Katja Adam; Ruediger Hehlmann; Dieter Buchheidt
Journal: Eur J Haematol Date: 2007-12-10 Impact factor: 2.997

Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome.

1. A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults.

Review 2. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.

3. Managing tumor lysis syndrome in 2010.

4. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.

Review 5. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.

6. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.

7. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial.

Review 8. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.

9. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.

Review 10. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.

1. Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.

Review 2. Medical and alternative therapies in urinary tract stone disease.

3. Evaluation of Rasburicase Use in the Fraser Health Authority: A Retrospective Review.

Review 4. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.